NeuroScientific Biopharmaceuticals Investor Relations Material
Latest events
M&A Announcement
30 Jun, 2025
Q3 2025 TU
23 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from NeuroScientific Biopharmaceuticals Limited
Access all reports
NeuroScientific Biopharmaceuticals Limited is a biotechnology company focused on researching and developing therapies for neurodegenerative diseases and neurotrauma. The company’s work centers on novel peptide-based treatments aimed at conditions such as Alzheimer’s disease, multiple sclerosis, and other neurological disorders that involve degeneration or damage to nerve cells. The company is headquartered in Perth, Australia, and its shares are listed on the ASX.
Key slides for NeuroScientific Biopharmaceuticals Limited
M&A Announcement
NeuroScientific Biopharmaceuticals Limited
M&A Announcement
NeuroScientific Biopharmaceuticals Limited
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
NSB
Country
🇦🇺 Australia